A Proof of Concept, Multi-centre, Clinical Trial of the Combination Cediranib-Olaparib at the Time of Disease Progression on PARP Inhibitor in Ovarian Cancer
Phase of Trial: Phase III
Latest Information Update: 20 Mar 2017
At a glance
- Drugs Cediranib (Primary) ; Olaparib (Primary)
- Indications Ovarian cancer
- Focus Proof of concept; Therapeutic Use
- 07 Jun 2017 Biomarkers information updated
- 15 Mar 2017 Planned End Date changed from 1 Jan 2019 to 1 Oct 2021.
- 15 Mar 2017 Planned primary completion date changed from 1 Mar 2018 to 1 Apr 2021.